Delving into the Latest Updates on SHR-6934 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

SHR-6934

Target-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Heart Failure

Inactive Indication-

Originator Organization

Beijing Suncadia Pharmaceuticals Co., Ltd

Active Organization

Shanghai MabGen Biotech Ltd

Beijing Tuojie Biomedical Technology Co., Ltd.Beijing Suncadia Pharmaceuticals Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of single and multiple subcutaneous injections of SHR-6934 injection in healthy subjects. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics and immunogenicity of single and multiple subcutaneous injections of SHR-6934 injection in healthy subjects; To evaluate the effect of SHR-6934 on the QT interval.

Start Date-

Sponsor / Collaborator

Beijing Tuojie Biomedical Technology Co., Ltd.

[+2]

100 Clinical Results associated with SHR-6934

Login to view more data

100 Translational Medicine associated with SHR-6934

Login to view more data

100 Patents (Medical) associated with SHR-6934

Login to view more data

100 Deals associated with SHR-6934

Login to view more data